EUPRAXIA PHARMACEUTICALS INC.
EUPRAXIA PHARMACEUTICALS INC. (EPRX): 1 pipeline candidate · 2 upcoming catalysts · ~9 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.6 months
D/E 0.07 · 0% dilution
Lead: Phase 1/Phase 2
1 candidate
2 upcoming, next in ~104d
N/A
A transparent, data-derived signal for EUPRAXIA PHARMACEUTICALS INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$406.3M
Cash
$80.6M
Quarterly Burn
$28.6M
Runway
8.6 mo
Revenue
$0
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| ep-104gi | Phase 1/Phase 2 |
Upcoming Catalysts (2)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
49
Total value held
$97.9M
| Holder | Shares | Value |
|---|---|---|
| affinity asset advisors, llc | 1,589,005 | $11.5M |
| balyasny asset management l.p. | 1,350,000 | $9.8M |
| great point partners llc | 1,200,000 | $8.7M |
| scotia capital inc. | 1,342,178 | $7.2M |
| woodline partners lp | 881,102 | $6.4M |
| redmile group, llc | 700,000 | $5.1M |
| rubric capital management lp | 691,170 | $5.0M |
| squadron capital management llc | 680,000 | $4.9M |
| ally bridge group (ny) llc | 660,375 | $4.8M |
| pfm health sciences, lp | 540,871 | $3.9M |
Showing top 10 of 49 institutional holders of EUPRAXIA PHARMACEUTICALS INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in EUPRAXIA PHARMACEUTICALS INC.'s pipeline?
EUPRAXIA PHARMACEUTICALS INC. (EPRX) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is EUPRAXIA PHARMACEUTICALS INC.'s lead drug candidate?
EUPRAXIA PHARMACEUTICALS INC.'s most advanced tracked candidate is ep-104gi (Phase 1/Phase 2) for Eosinophilic Esophagitis.
What is EUPRAXIA PHARMACEUTICALS INC.'s next catalyst?
EUPRAXIA PHARMACEUTICALS INC.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: ep-104gi" — expected September 30, 2026.
What is EUPRAXIA PHARMACEUTICALS INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, EUPRAXIA PHARMACEUTICALS INC. has approximately 8.6 months of cash runway.
What is EUPRAXIA PHARMACEUTICALS INC.'s market capitalization?
EUPRAXIA PHARMACEUTICALS INC.'s market capitalization is approximately $406.3M.
Get the full picture on EUPRAXIA PHARMACEUTICALS INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.